中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2013年
24期
1903-1905
,共3页
肾肿瘤%干扰素类%分子靶向治疗%索拉非尼
腎腫瘤%榦擾素類%分子靶嚮治療%索拉非尼
신종류%간우소류%분자파향치료%색랍비니
Kidney neoplasms%Interferons%Molecular targeted therapy%Sorafenib
目的 探讨索拉非尼治疗晚期肾癌的效果和不良反应.方法 收集总结大连医科大学附属第一医院2007年4月至2011年10月泌尿外科门诊收治的有完整临床病理资料的晚期肾癌患者共57例,其中24例为索拉非尼组,33例为索拉非尼+干扰素组,研究的主要终点为客观反应率、无进展生存期,次要终点为总生存期、不良反应发生率.结果 索拉非尼组平均服药15(7 ～56)个月.其中部分缓解1例、疾病稳定8例、疾病进展1例,死亡14例,客观反应率4.2％ (1/24),疾病控制率37.5％ (9/24).索拉非尼+干扰素组平均服药15(4～30)个月,部分缓解2例、疾病稳定21例、疾病进展1例,死亡9例,客观反应率6.1％ (2/33),疾病控制率69.7％ (23/33).两组主要不良反应发生率和严重程度差异均无统计学意义(均P＞0.05).结论 索拉非尼治疗晚期肾癌安全有效,不良反应多数患者可耐受.加用干扰素治疗可显著提高治疗效果,而不良反应率并无增加.
目的 探討索拉非尼治療晚期腎癌的效果和不良反應.方法 收集總結大連醫科大學附屬第一醫院2007年4月至2011年10月泌尿外科門診收治的有完整臨床病理資料的晚期腎癌患者共57例,其中24例為索拉非尼組,33例為索拉非尼+榦擾素組,研究的主要終點為客觀反應率、無進展生存期,次要終點為總生存期、不良反應髮生率.結果 索拉非尼組平均服藥15(7 ～56)箇月.其中部分緩解1例、疾病穩定8例、疾病進展1例,死亡14例,客觀反應率4.2％ (1/24),疾病控製率37.5％ (9/24).索拉非尼+榦擾素組平均服藥15(4～30)箇月,部分緩解2例、疾病穩定21例、疾病進展1例,死亡9例,客觀反應率6.1％ (2/33),疾病控製率69.7％ (23/33).兩組主要不良反應髮生率和嚴重程度差異均無統計學意義(均P＞0.05).結論 索拉非尼治療晚期腎癌安全有效,不良反應多數患者可耐受.加用榦擾素治療可顯著提高治療效果,而不良反應率併無增加.
목적 탐토색랍비니치료만기신암적효과화불량반응.방법 수집총결대련의과대학부속제일의원2007년4월지2011년10월비뇨외과문진수치적유완정림상병리자료적만기신암환자공57례,기중24례위색랍비니조,33례위색랍비니+간우소조,연구적주요종점위객관반응솔、무진전생존기,차요종점위총생존기、불량반응발생솔.결과 색랍비니조평균복약15(7 ～56)개월.기중부분완해1례、질병은정8례、질병진전1례,사망14례,객관반응솔4.2％ (1/24),질병공제솔37.5％ (9/24).색랍비니+간우소조평균복약15(4～30)개월,부분완해2례、질병은정21례、질병진전1례,사망9례,객관반응솔6.1％ (2/33),질병공제솔69.7％ (23/33).량조주요불량반응발생솔화엄중정도차이균무통계학의의(균P＞0.05).결론 색랍비니치료만기신암안전유효,불량반응다수환자가내수.가용간우소치료가현저제고치료효과,이불량반응솔병무증가.
Objective To explore the efficacies and adverse events of sorafenib in the treatment of advanced metastatic renal cell carcinoma.Methods A total of 57 patients with advanced kidney cancer were recruited from our hospital from April 2007 to October 2011.They were divided into sorafenib group (A,n =24) and sorafenib + IFN group (B,n =33).The primary endpoints included objective response rate and progression-free survival (PFS).And the secondary endpoints were overall survival (OS) and incidence of adverse events.Results The mean medication time of group A was 15 (7-56) months.The outcomes were partial response (PR,n =1),stable disease (SD,n =8),progressive disease (PD,n =1)and death (n =14).The rates of objective response and disease control were 4.2％ (1/24) and 37.5％ (9/24) respectively.For group B,the mean medication time was 15 (4-30) months.The outcomes were PR (n =2),and include 2 patients of PR,21 examples of SD,1 patient of PD and death.The rates of objective response and disease control were 6.1％ (2/33) and 69.7％ (23/33) respectively.Two groups had no significant difference in incidence or severity of adverse events (both P ＞ 0.05).Conclusions As a safe and effective agent for advanced kidney cancer,sorafenib is well-tolerated in patients.The combined use of interferon may improve the therapeutic efficacies without an occurrence of adverse events.
